Adoptive immunotherapy with engineered T-cells, for example, CAR T-cells (Chimeric Antigen Receptor) is associated with significant toxicities including cytokine release syndrome, neurologic toxicity, “on target/off tumor” recognition, and anaphylaxis. CAR T-cells lack the ability to respond to signals that maintain immune homeostasis. For this reason, they are effective relentless killers of cells that express the target to which they have been programmed, however, at a safety cost. Continue reading
Tag Archives: Adoptive Immunotherapy
Early Cancer Detection Company, Grail, Led by Former Google VP – Ashley P. Angelo, Contributor
Healthcare firm Grail, which has been formed by the gene sequencing company Illumina, named Jeff Huber, former Google X Senior Vice President, as its CEO in February. With Huber’s experience in developing large-scale data, Grail hopes to improve gene sequencing technology used in blood tests for early detection of cancer in asymptomatic patients so that immunotherapeutic strategies, as opposed to toxic chemotherapy, can be employed with the goal of curing cancer. Continue reading
Novel mutated antigens from Tumor Infiltrating Lymphocytes from long-term melanoma responders
Tumor Infiltrating Lymphocytes (TILs) are cytotoxic T-cells that are found in tumors. They serve to destroy cancer, or at least keep cancer at bay. Adoptive immunotherapy, Continue reading